| In vitro: |
| J Antibiot (Tokyo). 1991 Mar;44(3):282-7. | | Lydicamycin, a new antibiotic of a novel skeletal type. I. Taxonomy, fermentation, isolation and biological activity.[Pubmed: 2026553] |
METHODS AND RESULTS:
A novel antibiotic, designated Lydicamycin, was isolated from the fermentation broth of an actinomycete strain identified as Streptomyces lydicus. Lydicamycin was active against Gram-positive bacteria and a certain yeast, but inactive against Gram-negative bacteria. | | J Antibiot (Tokyo). 2002 Oct;55(10):873-80. | | TPU-0037-A, B, C and D, novel lydicamycin congeners with anti-MRSA activity from Streptomyces platensis TP-A0598.[Pubmed: 12523820] |
METHODS AND RESULTS:
In screening for anti-MRSA antibiotics, novel Lydicamycin congeners, TPU-0037-A, B, C and D, were isolated from a culture broth of an actinomycete strain.
The producing strain, TP-A0598, was isolated from a seawater sample collected in Toyama Bay, Japan, and identified as Streptomyces platensis based on taxonomic characteristics. TPU-0037-A, B, C and D were purified by HP-20 resin, ODS column chromatographies and preparative HPLC, consecutively, and their structures were determined to be 30-demethylLydicamycin, 14,15-dehydro-8-deoxyLydicamycin, 30-demethyl-8-deoxyLydicamycin and 8-deoxyLydicamycin, respectively, by NMR and MS analyses.
CONCLUSIONS:
The new congeners showed antibiotic activity against gram-positive bacteria including MRSA with the MIC of 1.56 to approximately 12.5 microg/ml.
|
|
Cell. 2018 Jan 11;172(1-2):249-261.e12. doi: 10.1016/j.cell.2017.12.019.IF=36.216(2019)
Cell Metab. 2020 Mar 3;31(3):534-548.e5. doi: 10.1016/j.cmet.2020.01.002.IF=22.415(2019)
Mol Cell. 2017 Nov 16;68(4):673-685.e6. doi: 10.1016/j.molcel.2017.10.022.IF=14.548(2019)
ACS Nano. 2018 Apr 24;12(4): 3385-3396. doi: 10.1021/acsnano.7b08969.IF=13.903(2019)
Nature Plants. 2016 Dec 22;3: 16206. doi: 10.1038/nplants.2016.205.IF=13.297(2019)
Sci Adv. 2018 Oct 24;4(10): eaat6994. doi: 10.1126/sciadv.aat6994.IF=12.804(2019)